Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)


A Phase IIa Open-label, Dose Confirmation Study of Oral Clofarabine in Adult Patients Previously Treated for Myelodysplastic Syndromes(MDS)




There is no well accepted standard care for patients who fail or are intolerant to any of the currently approved therapies for Myelodysplastic Syndromes (MDS). In this study, patients will be assigned to receive 25mg of oral clofarabine daily for 5 days. Patients may receive up to 8 cycles of treatment with clofarabine as long as the patient continues to benefit and in the absence of progressive disease.

Study Status: Completed


Condition Intervention Phase
Myelodysplastic Syndromes
Secondary AML
Drug: clofarabine Phase 2

Verified by Genzyme December, 2011

Sponsored by: Genzyme
Information provided by: Genzyme identifier: NCT00531232

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Medical Monitor., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site